Move from the ingredient story to the exact product, study population and outcome. Those details determine what a claim can reasonably support.
Start by identifying the kind of evidence
A product page tells you what a provider markets. A prescribing label describes an approved medicine and its studied uses. A controlled trial answers a defined research question. A patient story describes an individual account. These sources serve different purposes and should not be treated as equal proof.
On this site, provider pages support catalog and pricing statements. FDA guidance and manufacturer labeling support regulatory and clinical context. The distinction allows useful product descriptions without treating every sentence of marketing as an established medical fact.[source]
Match the evidence to the preparation
Look for the exact formulation, route and product. An oral precursor is not the same preparation as injected NAD+. A branded semaglutide trial is not a study of every compounded semaglutide vial. A tretinoin study does not independently test every custom cream containing tretinoin.
FDA explains that compounded drugs are not FDA-approved and do not undergo the agency’s premarket review for safety, effectiveness and quality. Ingredient overlap cannot erase that finished-product distinction.[source]
Ask what was actually measured
A laboratory marker, a biological mechanism and a patient-important improvement are different outcomes. A statement that a molecule participates in cellular energy does not establish that a product improves fatigue or extends life. A change in a survey score is not automatically a controlled clinical result.
For a study, identify the participants, comparison group, follow-up and absolute result. Ask whether that setting resembles the intended use. The absence of a verified trial in this review means a benefit has not been established here; it is not a claim that every conceivable benefit is impossible.
Be especially careful with supplement blends
NIH ODS notes that probiotic effects depend on the specific organisms and outcomes studied. A product with several strains cannot borrow the results of any probiotic trial merely because the word probiotic appears on both labels.[source]
The same reasoning applies to mixed greens or fiber formulas. Review the actual label, amounts and quality information. A recognizable ingredient list is a starting point for research, not proof that the finished combination produces a promised outcome.
Use uncertainty in the decision
Ask the clinician what is known, what remains uncertain and which alternative has stronger support for the intended goal. The answer may be different for a defined medical indication and a broad wellness aspiration.
Commercial placement should also be visible. CoreAge Rx is first here because it is featured commercially, not because we ran comparative clinical trials. The methodology explains the boundary between review, source verification and medical evaluation.
Sources & further reading
Provider pages establish what a brand markets. Clinical and regulatory sources establish the limits of the evidence. Accessed October 8, 2026.
- FDA — Compounding and the FDA: Questions and AnswersCompounded drugs are not FDA-approved; oversight and evidence limitations
- NIH ODS: probioticsStrain-specific evidence and supplement-label considerations